Improving the managed entry of new medicines: sharing experiences across Europe

被引：0

作者：

Godman, Brian ^{[1
,2
,3
]}

Paterson, Ken ^{[4
]}

Malmstrom, Rickard E. ^{[5
]}

Selke, Gisbert ^{[6
]}

Fagot, Jean-Paul ^{[7
]}

Mrak, Jana ^{[8
]}

机构：

[1] Karolinska Univ, Huddinge Hosp, Div Clin Pharmacol, Stockholm, Sweden

[2] Mario Negri Inst Pharmacol Res, Milan, Italy

[3] Univ Liverpool, Prescribing Res Grp, Sch Management, Liverpool L69 3BX, Merseyside, England

[4] Scottish Med Consortium, Glasgow, Lanark, Scotland

[5] Karolinska Univ, Hosp Solna, Karolinska Inst, Dept Med,Div Clin Pharmacol, Stockholm, Sweden

[6] AOK WidO, Wissensch Inst, Berlin, Germany

[7] Caisse Natl Assurance Maladie Travailleurs Salari, DSES, DEPP, Paris, France

[8] Hlth Insurance Inst Slovenia, Ljubljana, Slovenia

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2012年 / 12卷 / 04期

关键词：

demand-side measures; horizon scanning; HTA; indicators; managed entry; pharmaceuticals; RECOMMENDATIONS; CARE; RISK;

D O I：

10.1586/ERP.12.44

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The Managed Introduction of New Medicines Ljubljana, Slovenia, 19-21 March 2012 The 3-day course on the managed entry of new medicines was run by the Piperska group, which is a pan-European group striving to enhance the health of the public as a whole and the individual patient through exchanging ideas and research around the rational use of drugs. Participants included health authority and health insurance personnel, academics and those from commercial organizations. The principal aim of the conference was to bring together people to discuss ways to improve the managed entry of new drugs.

引用

页码：439 / 441

页数：3

共 50 条

[1] Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe
Matusewicz, Wojciech
Godman, Brian
Pedersen, Hanne Bak
Fuerst, Jurij
Gulbinovic, Jolanta
Mack, Asbjorn
Selke, Gisbert
Timoney, Angela
Warminska, Ewa
Malmstrom, Rickard E.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (05) : 755 - 758
[2] Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
Ciulla, Michele
Marinelli, Lisa
Di Biase, Giuseppe
Cacciatore, Ivana
Santoleri, Fiorenzo
Costantini, Alberto
Dimmito, Marilisa Pia
Di Stefano, Antonio
HEALTHCARE, 2023, 11 (03)
[3] Australian Managed Entry Scheme: A New Manageable Process for the Reimbursement of New Medicines?
Wonder, Michael
Backhouse, Martin E.
Sullivan, Sean D.
VALUE IN HEALTH, 2012, 15 (03) : 586 - 590
[4] ASSESSMENT OF MANAGED ENTRY AGREEMENTS IN EUROPE AND THE US
Fortier, K.
Riodin, E. L.
Nadkarni, S.
VALUE IN HEALTH, 2017, 20 (05) : A65 - A65
[5] Improving adherence-sharing experiences
Burkiewicz, Jill S.
Fit, Kathy E.
ANNALS OF PHARMACOTHERAPY, 2007, 41 (12) : 2058 - 2060
[6] Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
Bouvy, Jacoline C.
Sapede, Claudine
Garner, Sarah
FRONTIERS IN PHARMACOLOGY, 2018, 9
[7] Risk sharing in managed entry agreements-A review of the Swedish experience
Andersson, Emelie
Svensson, Johanna
Persson, Ulf
Lindgren, Peter
HEALTH POLICY, 2020, 124 (04) : 404 - 410
[8] Europe adopts new legislation on medicines
不详
VETERINARY RECORD, 2004, 154 (13) : 383 - 384
[9] The critical path to new medicines: Data sharing
不详
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2006, 34 (03): : 273 - 274
[10] Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
Jommi, Claudio
Addis, Antonio
Martini, Nello
Nicod, Elena
Pani, Marcello
Scopinaro, Annalisa
Vogler, Sabine
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 114 - 119

← 1 2 3 4 5 →